Illumina reagents and consumables for NCI
Ended Awarded Last action
- Contract number
- 75N91026F00003
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $248,335
Award facts
- Contract value 100% obligated
- $248,334.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a delivery order valued at $248,334.98 to Illumina, Inc. for reagents and consumables supporting NCI's genomic research initiatives. The firm fixed-price delivery order was issued on February 27, 2026, with an ultimate completion date of August 31, 2026, and carries no set-aside designation. Illumina, a San Diego-based biotechnology company specializing in genetic sequencing and genomic analysis technologies, will fulfill this order from its San Diego, California location. This award reflects NCI's continued reliance on Illumina's comprehensive portfolio of sequencing reagents and consumables to support the Institute's cancer research and diagnostics programs.
This delivery order leverages Illumina's established relationship with the National Institutes of Health enterprise, where the company has demonstrated extensive contracting experience across multiple NIH institutes and centers. Illumina's proprietary sequencing platforms and associated consumables are integral to contemporary genomic research, positioning the company as a primary supplier for federal cancer research operations. The delivery order structure enables NCI to procure critical laboratory materials efficiently while maintaining access to Illumina's specialized genetic analysis capabilities that support the Institute's mission to reduce cancer incidence and improve patient outcomes through advanced genomic research.
Quick answers
Who was awarded contract 75N91026F00003?
75N91026F00003 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on February 27, 2026.
How much is contract 75N91026F00003 worth?
The government has obligated $248,335 on 75N91026F00003.
Is contract 75N91026F00003 an order under another contract?
Yes. 75N91026F00003 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N91026F00003 competed?
The extent of competition for 75N91026F00003 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award